Skip to content


Wakix (pitolisant) is a small molecule pharmaceutical. Pitolisant was first approved as Wakix on 2016-03-31. It has been approved in Europe to treat narcolepsy. The pharmaceutical is active against histamine H3 receptor. In addition, it is known to target histamine H4 receptor, histamine H2 receptor, and histamine H1 receptor. Wakix's patents are valid until 2029-09-26 (FDA).
Trade Name Wakix
Common Name Pitolisant
Indication narcolepsy
Drug Class Histamine H3 receptor antagonists
Get full access now